Navigation Links
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
Date:4/7/2008

Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the

Clinical Gold Standard Through 2016, According to a New Report from

Decision Resources

WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on inhibiting/slowing the progression of structural damage and reducing the signs and symptoms of rheumatoid arthritis during the first year of treatment are the attributes that most influence surveyed rheumatologists' prescribing decisions in the treatment of the disease. Clinical data and expert opinion shows that current and emerging therapies have no advantage in these attributes over the market sales leader, Amgen/Wyeth/Takeda's Enbrel.

The new report entitled Rheumatoid Arthritis: Competitive, Crowded Market Sets the Bar High for Novel Agents finds that, through 2016, there are no therapies in development that will displace Enbrel as the clinical gold standard treatment for rheumatoid arthritis. While some therapies in development for the disease hold promise, most have efficacy, safety and tolerability, and/or delivery features that are inferior when compared with Enbrel.

The overall efficacy of emerging therapies such as Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Biogen Idec/Genentech/Roche's ocrelizumab is comparable to that of Enbrel, while the overall safety and tolerability for emerging therapies that include ocrelizumab and UCB's Cimzia are also comparable to that of Enbrel. However, the currently available clinical data for golimumab, ocrelizumab and Cimzia is not as robust or extensive as those available for Enbrel.

"While emerging therapies such as golimumab and Cimzia offer superior delivery to that of Enbrel due to improved dosing frequencies, these agents' overall efficacy, safety and tolerability, respectively, are inferior to those of Enbrel-and efficacy, safety and tolerability are weighted more heavily by surveyed rheumatologists as key drivers of prescribing decisions," said Cindy Mundy, Ph.D., director at Decision Resources. "As a result, the improvements in dosing frequency that golimumab and Cimzia offer over Enbrel are not sufficient to propel either agent to the position of future gold standard."

About the Report

Rheumatoid Arthritis: Competitive, Crowded Market Sets the Bar High for Novel Agents is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
2. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
3. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
6. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016   Health 2.0 , the ... health technologies, announced today " 10 Year Global Retrospective ... tech over the past ten years.   ... decade, Health 2.0 has served as the preeminent thought-leader ... with thousands of technologies, companies, innovators, and patient-activists through ...
(Date:2/11/2016)...  AfterPill.com is reporting that this week,s Centers for ... women who are at risk of unintended pregnancy impacts ... raises the risks of unprotected sex in particular.  ... to the Guttmacher Institute, there are 43 million women ... who have sex without the intention of becoming pregnant.  ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and ... --> Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and ... future growth with most robust pipeline in Shire , ... growth with most robust pipeline in Shire , ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... healthcare industry, ranked among the top five firms in the “2015/2016 Best in ... Implementation Support and Staffing. KLAS is a research and insights firm on a ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... and Reconstructive Surgery, Dallas plastic surgeon , Dr. Rod J. Rohrich, and ... surgery . Dr. Rohrich outlines recommendations for rhinoplasty surgeons when addressing this vital ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... clinical decision support technology, with highly adaptable algorithms, has been updated to help ... has signs and symptoms consistent with Zikas and a travel history to affected ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you ... Ray Clarke poses a question as a challenge for his readers to examine ... in the Being" (published by Partridge Singapore), Clarke explores the subject with more ...
Breaking Medicine News(10 mins):